ClinicalTrials.gg
CompletedNCT05112159Updated May 1, 2026Results posted

Phase 1 Study of IPG1094 Safety, Tolerability, and PK in Healthy Participants

A Phase 1 interventional study of IPG1094 300 mg SAD and IPG1094 600 mg SAD in Healthy Volunteers, sponsored by Nanjing Immunophage Biotech Co., Ltd. Completed at 1 site in Australia. Open to participants aged 18 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-05-01.

Sponsored by Nanjing Immunophage Biotech Co., Ltd · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
76
Allocation
Randomized
Ages
18 Years to 50 Years
Sex
All
01

Study summary

This is a phase 1, first-in-human, randomized, double-blind, placebo-controlled, single dose escalation study to evaluate the safety, tolerability, and PK of single dose orally administered IPG1094 in healthy adult participants.

02

Conditions studied

  • Healthy Volunteers

Keywords

  • Healthy Volunteers
03

In context

Lead sponsor

Nanjing Immunophage Biotech Co., Ltd is the lead sponsor of 11 studies on the registry; 6 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Participants must meet all of the following criteria to be included in the study:

Demography

  1. Healthy adult male or female participants between 18 and 50 years of age (inclusive).
  2. Body weight between 50 and 100 kg (inclusive) and (BMI) within 18\~32 kg/m2 (inclusive).

    Health status

  3. In good health as determined by screening tests. Good health is defined as having no abnormalities identified by a detailed medical history, full physical examination (including measurement of blood pressure and pulse rate), 12-lead , and clinical laboratory tests.

    Vital signs (measured after resting for 5 minutes seated position) within normal range, or outside the normal range and not considered clinically significant by the Investigator.

    Standard 12-lead ECG parameters (recorded after resting for 5 minutes in supine position) in the following ranges; interval(QTc) (Fridericia algorithm recommended) ≤ 450 ms for males and 470 ms for females, and normal ECG tracing, or abnormal ECG tracing not considered clinically relevant by the Investigator.

    Laboratory parameters demonstrating no clinically significant abnormalities, as determined by the Investigator. A total outside the normal range may be acceptable if total bilirubin does not exceed 1.5 × (ULN) conjugated bilirubin (with the exception of a participant with documented Gilbert syndrome).

  4. A negative result on urine drug screen and a repeat negative result on Day -1 (amphetamines/methamphetamines, barbiturates, benzodiazepines, cannabinoids, cocaine, opiates).
  5. Female participants must not be pregnant or breastfeeding and must use an effective method (as described in Section 4.5.4), with the exception of participants who have undergone sterilization in the preceding 3 months, or who are .

    A woman of (WOCBP) must undergo pregnancy testing prior to the first dose of the Medicinal Product (IMP). The participant must be excluded from the study if the serum pregnancy test is positive.

    A postmenopausal state is defined as 12 months of amenorrhea without an alternative medical cause. In the absence of 12 months of amenorrhea, menopause may be confirmed by follicle stimulating hormone(FSH) measurement (> 40 IU/L or milli-International unit(mIU)/mL).Females on Hormonal Replacement therapy (HRT ), where menopausal status is indeterminate, will be required to use a non-estrogen hormonal contraceptive method if participants wish to continue their HRT during the study. Participants must otherwise discontinue HRT to allow for confirmation of postmenopausal status prior to enrollment in the study.

    Regulation

  6. Provide written prior to undertaking any study-related procedures.
  7. Must not be under any administrative or legal supervision or under institutionalization as per a regulatory or juridical order.

Exclusion criteria

Exclusion Criteria:

Participants who meet any of the following criteria will be excluded from the study:

Medical history and clinical status

  1. Any history or presence of cardiovascular, pulmonary, gastrointestinal, hepatic, renal, metabolic, hematological, neurological, musculoskeletal, rheumatological, psychiatric, systemic, ocular, or infectious disease, or signs of acute illness.
  2. Frequent severe headaches and/or migraines, recurrent nausea and/or vomiting (defined as vomiting more than twice a month).
  3. Made a blood donation of any volume within 2 months prior to the first dose.
  4. Symptomatic postural hypotension, irrespective of actual decrease in blood pressure, or asymptomatic postural hypotension with a decrease in systolic blood pressure ≥30 mmHg within 3 minutes of moving from supine to standing position.
  5. Presence or history of drug , or anaphylactic reaction, diagnosed and treated by a physician.
  6. Known hypersensitivity to any component of the IMP formulation.
  7. History or presence of drug or alcohol abuse (defined as alcohol consumption more than 2 units per day on a regular basis).
  8. Regular smoking (defined as more than 5 cigarettes or equivalent per week), or unable to stop smoking during the study. Occasional smokers may be enrolled.
  9. Excessive consumption of beverages containing xanthine bases (defined as more than 4 glasses per day).

    Interfering substances

  10. Any medication, including St John's Wort, within 14 days prior to administration of the first dose or within 5 times the elimination half-life or pharmacodynamic half-life of the medication, with the exception of hormonal , menopausal hormone replacement therapy, or occasional paracetamol at doses up to 2g/day.
  11. Any consumption of grapefruit or products containing grapefruit within 5 days prior to the first dose administration.
  12. Any vaccination in the 28 days prior to administration of the first dose.

    General conditions

  13. Any participant who, in the judgment of the Investigator, is likely to be non-compliant during the study, or to be unable to cooperate due to language problems or poor mental development.
  14. Any participant who enrolled in or participated in any other clinical study involving an medicinal product, or in any other type of medical research within 1 month or within 5 times the elimination half-life prior to administration of the first dose.
  15. Any participant who cannot be contacted in the case of an emergency.
  16. Any participant who is the Investigator or any sub-investigator, research assistant, pharmacist, study coordinator, or other staff thereof directly involved in conducting the study or any person dependent on (employees or immediate family members) the study site, the Investigator or the Sponsor.

    Biological status

  17. Positive result on any of the following tests: surface antigen (HBsAg), hepatitis B core antibodies (HBcAb), anti- virus antibodies (anti-HCV), anti- 1 and 2 antibodies(anti-HIV1 and anti-HIV2 Ab).
  18. Positive alcohol test.
  19. Any participant in whom venous blood collection is difficult.
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
76 participants (actual)

Study arms

  • Experimental
    IPG1094 100 mg SAD

    Four subjects in this cohort will receive a single dose of IPG1094 100 mg and two subjects will receive a single dose of placebo 100 mg orally.

    Drug: IPG1094 100 mg SAD

  • Experimental
    IPG1094 300 mg SAD

    Six subjects in this cohort will receive a single dose of IPG1094 300 mg and two subjects will receive a single dose of placebo 300 mg orally.

    Drug: IPG1094 300 mg SAD

  • Experimental
    IPG1094 600 mg SAD

    Six subjects in this cohort will receive a single dose of IPG1094 600 mg and two subjects will receive a single dose of placebo 600mg orally.

    Drug: IPG1094 600 mg SAD

  • Experimental
    IPG1094 900mg SAD

    Six subjects in this cohort will receive a single dose of IPG1094 900 mg qd and two subjects will receive a single dose of placebo 900mg qd orally.

    Drug: IPG1094 900 mg SAD

  • Experimental
    IPG1094 1200mg SAD

    Six subjects in this cohort will receive a single dose of IPG1094 1200 mg and two subjects will receive a single dose of placebo 1200 mg orally.

    Drug: IPG1094 1200 mg SAD

  • Experimental
    IPG1094 600 mg MAD QD

    Dosing begins on Day 1 and continues for 10 days with daily doses of 600 mg QD. Subjects are discharged on Day 14, followed by a 7-day post-dosing follow-up. Six subjects in this cohort will receive IPG1094 600 mg and two subjects will receive placebo.

    Drug: IPG1094 600 mg MAD QD

  • Experimental
    IPG1094 200 mg MAD BID

    Dosing begins on Day 1 and continues for 10 days with twice daily 200 mg. Subjects are discharged on Day 14, followed by a 7-day post-dosing follow-up. Six subjects in this cohort will receive IPG1094 200 mg nd two subjects will receive placebo.

    Drug: IPG1094 200 mg MAD BID

  • Experimental
    IPG1094 300 mg MAD BID

    Dosing begins on Day 1 and continues for 10 days with twice daily 300 mg. Subjects are discharged on Day 14, followed by a 7-day post-dosing follow-up. Six subjects in this cohort will receive IPG1094 300 mg and two subjects will receive placebo.

    Drug: IPG1094 300 mg MAD BID

  • Experimental
    IPG1094 300 mg Fasted-Fed

    For Cohort FE-1, Six subjects administration of a single dose of IPG1094 would occur on Day 1 of Period 1 under the fasted condition, and Day 5 (anticipated) of Period 2 under the fed condition. 300 mg per administration.

    Drug: IPG1094 300 mg Fasted-Fed

  • Experimental
    Part D IPG1094 300 mg Fed-Fasted

    For Cohort FE-2, Six subjects administration of a single dose of IPG1094 would occur on Day 1 of Period 1 under the fed condition, and Day 5 (anticipated) of Period 2 under fasted condition. 300 mg per administration.

    Drug: IPG1094 300 mg Fed-Fasted

Interventions

  • a Single-dose Treatment Period of 1 day, and a Follow-up period of 7 days,300 mg, QD, 3 tablets

  • A Single-dose Treatment Period of 1 day, and a Follow-up period of 7 days, 600 mg, QD, 6tablets

  • A Single-dose Treatment Period of 1 day, and a Follow-up period of 7 days,900 mg, QD, 9tablets

  • A Single-dose Treatment Period of 1 day, and a Follow-up period of 7 days,1200 mg, QD, 12 tablets

  • Dosing begins on Day 1 and continues for 10 days with daily doses of 600 mg QD.

  • Dosing starts on Day 1 and extends over a 10-day period. Subjects are discharged on Day 13, with a follow-up 7 days after the last dose, each cohort comprises approximately eight subjects, with 6 subjects on IPG1094 and 2 subjects on placebo

  • Dosing starts on Day 1 and extends over a 10-day period. Subjects are discharged on Day 13, with a follow-up 7 days after the last dose, each cohort comprises approximately eight subjects, with 6 subjects on IPG1094 and 2 subjects on placebo

  • For Cohort FE-2, administration of a single dose of IPG1094 would occur on Day 1 of Period 1 under the fed condition, and Day 5 (anticipated) of Period 2 under fasted condition.

  • For Cohort FE-1, administration of a single dose of IPG1094 would occur on Day 1 of Period 1 under the fasted condition, and Day 5 (anticipated) of Period 2 under the fed condition.

  • a Single-dose Treatment Period of 1 day, and a Follow-up period of 7 days,100 mg, QD, 1 tablets

06

What researchers measure

Primary outcomes

  1. Adverse Events

    Evaluation of adverse events

    Time frame: Part A (SAD):From signed ICF up to D8;Part B (MAD):From signed ICF up to D17;Part C (MAD):From signed ICF up to D17;Part D (FE):From signed ICF up to D12;

Secondary outcomes

  1. Cmax

    Maximum observed concentration Part A: at 0h before administration(within 1h prior toadministration),0.5,1,1.5,2,2.5,3,4,6,9,12,24,36,48,72,and 96 h after administration. Part B: at 0h before AMadministration(within 1h before AM administration),0.5,1,1.5,2,2.5,3,4,6,9,12,24h after administration on Day 1 and Day 10;at 0h beforeadministration(within 1h prior to administration)on day 4,day 6 and Day 8;at 36,48,72,and 96h after thelast administration on Day 10. Part C: 0h before AMadministration(within 1h before AM administration),0.5,1,1.5,2,2.5,3,4,6,9,12(within 1h before PMadministration),24h(within 1h beforeAMadministration of Day 2)after administration on Day 1 and Day 10;at 0h before administration(within1h priorto AM administration)on day 3,day4,day 5 day 6 and Day 8;at 48,72h after the AM administrationon Day 10. Part D:pre-dose(within 1h before administration),0.5,1,1.5,2,2.5,3,4,5,6,9,12,24,36,48,72h after administration.

    Time frame: Part A: UP to D5 Part B: UP to D14 Part C: Up to D13 Part D: UP to D12

  2. Tmax

    Time of maximum observed concentration Part A: at 0h before administration(within 1h prior toadministration),0.5,1,1.5,2,2.5,3,4,6,9,12,24,36,48,72,and 96 h after administration. Part B: at 0h before AMadministration(within 1h before AM administration),0.5,1,1.5,2,2.5,3,4,6,9,12,24h after administration on Day 1 and Day 10;at 0h beforeadministration(within 1h prior to administration)on day 4,day 6 and Day 8;at 36,48,72,and 96h after thelast administration on Day 10. Part C: 0h before AMadministration(within 1h before AM administration),0.5,1,1.5,2,2.5,3,4,6,9,12(within 1h before PMadministration),24h(within 1h beforeAMadministration of Day 2)after administration on Day 1 and Day 10;at 0h before administration(within1h priorto AM administration)on day 3,day4,day 5 day 6 and Day 8;at 48,72h after the AM administrationon Day 10. Part D:pre-dose(within 1h before administration),0.5,1,1.5,2,2.5,3,4,5,6,9,12,24,36,48,72h after administration.

    Time frame: Part A: UP to D5 Part B: UP to D14 Part C: Up to D13 Part D: UP to D12

  3. AUC0-t

    The parameter would be calculated using the linear trapezoidal rule: Linear up log down. Part A: 0h before administration(within 1h prior toadministration),0.5,1,1.5,2,2.5,3,4,6,9,12,24,36,48,72,and 96 h after administration. Part B: 0h before AMadministration(within 1h before AM administration),0.5,1,1.5,2,2.5,3,4,6,9,12,24h after administration on Day 1 and Day 10;at 0h beforeadministration(within 1h prior to administration)on day 4,day 6 and Day 8;at 36,48,72,and 96h after thelast administration on Day 10. Part C: 0h before AMadministration(within 1h before AM administration),0.5,1,1.5,2,2.5,3,4,6,9,12(within 1h before PMadministration),24h(within 1h beforeAMadministration of Day 2)after administration on Day 1 and Day 10;at 0h before administration(within1h priorto AM administration)on day 3,day4,day 5 day 6 and Day 8;at 48,72h after the AM administrationon Day 10. Part D:pre-dose(within 1h before administration),0.5,1,1.5,2,2.5,3,4,5,6,9,12,24,36,48,72h after administration

    Time frame: Part A: UP to D5 Part B: UP to D14 Part C: Up to D13 Part D: UP to D12

  4. CL/F

    Apparent clearance following extravascular administration, calculated as Dose/AUC0-inf Part A: 0h before administration(within 1h prior toadministration),0.5,1,1.5,2,2.5,3,4,6,9,12,24,36,48,72,and 96 h after administration. Part B: 0h before AMadministration(within 1h before AM administration),0.5,1,1.5,2,2.5,3,4,6,9,12,24h after administration on Day 1 and Day 10;at 0h beforeadministration(within 1h prior to administration)on day 4,day 6 and Day 8;at 36,48,72,and 96h after thelast administration on Day 10. Part C: 0h before AMadministration(within 1h before AM administration),0.5,1,1.5,2,2.5,3,4,6,9,12(within 1h before PMadministration),24h(within 1h beforeAMadministration of Day 2)after administration on Day 1 and Day 10;at 0h before administration(within1h priorto AM administration)on day 3,day4,day 5 day 6 and Day 8;at 48,72h after the AM administrationon Day 10. Part D:pre-dose(within 1h before administration),0.5,1,1.5,2,2.5,3,4,5,6,9,12,24,36,48,72h after administration

    Time frame: Part A: UP to D5 Part B: UP to D14 Part C: Up to D13 Part D: UP to D12

07

Results

Posted May 1, 2026

Participant flow

Participant flow — Overall Study
MilestonePart A :100 mg SADPart A : 300 mg SADPart A : 600 mg SADPart A : 900mg SADPart A : 1200mg SADPart B : 600 mg QD MADPart C : 200 mg BID MADPart C : 300 mg BID MADPartA: PlaceboPartB: PlaceboPart C: PlaceboPart D 300 mg Fasted-FedPart D 300 mg Fed-Fasted
Started46666676102476
Completed46666460102266
Not completed0000021600210
Withdrew: Adverse event0000010600000
Withdrew: Withdrawal by subject0000011000010
Withdrew: Physician decision0000000000200

Outcome measures

PrimaryAdverse Events

Evaluation of adverse events

Time frame:
Part A (SAD):From signed ICF up to D8;Part B (MAD):From signed ICF up to D17;Part C (MAD):From signed ICF up to D17;Part D (FE):From signed ICF up to D12;
Reported as:
Count of participants · Participants
Adverse Events
ParticipantsPartA: IPG1094 100 mg SADPartA: IPG1094 300 mg SADPartA: IPG1094 600 mg SADPartA: IPG1094 900mg SADPartA: IPG1094 1200mg SADPartB: IPG1094 600 mg MAD QDPartC: IPG1094 200 mg MAD BIDPartC: IPG1094 300 mg MAD BIDPart D:IPG1094 300mg FastedPartD: IPG1094 300mg FedPartA: PlaceboPartB: PlaceboPart C: Placebo
Adverse Events0233666657522
SecondaryCmax

Maximum observed concentration Part A: at 0h before administration(within 1h prior toadministration),0.5,1,1.5,2,2.5,3,4,6,9,12,24,36,48,72,and 96 h after administration. Part B: at 0h before AMadministration(within 1h before AM administration),0.5,1,1.5,2,2.5,3,4,6,9,12,24h after administration on Day 1 and Day 10;at 0h beforeadministration(within 1h prior to administration)on day 4,day 6 and Day 8;at 36,48,72,and 96h after thelast administration on Day 10. Part C: 0h before AMadministration(within 1h before AM administration),0.5,1,1.5,2,2.5,3,4,6,9,12(within 1h before PMadministration),24h(within 1h beforeAMadministration of Day 2)after administration on Day 1 and Day 10;at 0h before administration(within1h priorto AM administration)on day 3,day4,day 5 day 6 and Day 8;at 48,72h after the AM administrationon Day 10. Part D:pre-dose(within 1h before administration),0.5,1,1.5,2,2.5,3,4,5,6,9,12,24,36,48,72h after administration.

Time frame:
Part A: UP to D5 Part B: UP to D14 Part C: Up to D13 Part D: UP to D12
Reported as:
Mean · ng/mL
Cmax
ng/mLPart A: IPG1094 100 mg SADPart A: IPG1094 300 mg SADPart A: IPG1094 600 mg SADPart A: IPG1094 900mg SADPart A: IPG1094 1200mg SADPart B: IPG1094 600 mg MAD QDPart C: IPG1094 200 mg MAD BIDPart C: IPG1094 300 mg MAD BIDPart D: IPG1094 300mg FastedPartD: IPG1094 300mg Fed
the SAD group and the single-dose administration (D1) of the MAD group and fasted &Fed status508 ± 2622180 ± 10005500 ± 21608330 ± 303018800 ± 62504860 ± 23701400 ± 6994650 ± 24802280 ± 18805630 ± 2230
The Cmax data of the MAD group after multiple administrations (D10)—————15800 ± 175008830 ± 2860———
SecondaryTmax

Time of maximum observed concentration Part A: at 0h before administration(within 1h prior toadministration),0.5,1,1.5,2,2.5,3,4,6,9,12,24,36,48,72,and 96 h after administration. Part B: at 0h before AMadministration(within 1h before AM administration),0.5,1,1.5,2,2.5,3,4,6,9,12,24h after administration on Day 1 and Day 10;at 0h beforeadministration(within 1h prior to administration)on day 4,day 6 and Day 8;at 36,48,72,and 96h after thelast administration on Day 10. Part C: 0h before AMadministration(within 1h before AM administration),0.5,1,1.5,2,2.5,3,4,6,9,12(within 1h before PMadministration),24h(within 1h beforeAMadministration of Day 2)after administration on Day 1 and Day 10;at 0h before administration(within1h priorto AM administration)on day 3,day4,day 5 day 6 and Day 8;at 48,72h after the AM administrationon Day 10. Part D:pre-dose(within 1h before administration),0.5,1,1.5,2,2.5,3,4,5,6,9,12,24,36,48,72h after administration.

Time frame:
Part A: UP to D5 Part B: UP to D14 Part C: Up to D13 Part D: UP to D12
Reported as:
Median · h
Tmax
hPart A: IPG1094 100 mg SADPart A: IPG1094 300 mg SADPart A: IPG1094 600 mg SADPart A: IPG1094 900mg SADPart A: IPG1094 1200mg SADPart B: IPG1094 600 mg MAD QDPart C: IPG1094 200 mg MAD BIDPart C: IPG1094 300 mg MAD BIDPartD: IPG1094 300mg FastedPartD: IPG1094 300mg Fed
the SAD group and the single-dose administration (D1) of the MAD group and fasted &Fed status3.19 (2.52 to 5.7)2.55 (2.42 to 3.92)5.91 (2.45 to 6.00)2.98 (2.45 to 9.00)7.49 (4.00 to 9.00)3.04 (2.43 to 3.92)2.03 (1.15 to 4.2)3.98 (3.00 to 4.00)4.36 (1.42 to 12.07)4.81 (1.97 to 9.00)
The Tmax data of the MAD group after multiple administrations (D10)—————2.72 (2.3 to 6.28)1.43 (0.92 to 6.03)———
SecondaryAUC0-t

The parameter would be calculated using the linear trapezoidal rule: Linear up log down. Part A: 0h before administration(within 1h prior toadministration),0.5,1,1.5,2,2.5,3,4,6,9,12,24,36,48,72,and 96 h after administration. Part B: 0h before AMadministration(within 1h before AM administration),0.5,1,1.5,2,2.5,3,4,6,9,12,24h after administration on Day 1 and Day 10;at 0h beforeadministration(within 1h prior to administration)on day 4,day 6 and Day 8;at 36,48,72,and 96h after thelast administration on Day 10. Part C: 0h before AMadministration(within 1h before AM administration),0.5,1,1.5,2,2.5,3,4,6,9,12(within 1h before PMadministration),24h(within 1h beforeAMadministration of Day 2)after administration on Day 1 and Day 10;at 0h before administration(within1h priorto AM administration)on day 3,day4,day 5 day 6 and Day 8;at 48,72h after the AM administrationon Day 10. Part D:pre-dose(within 1h before administration),0.5,1,1.5,2,2.5,3,4,5,6,9,12,24,36,48,72h after administration

Time frame:
Part A: UP to D5 Part B: UP to D14 Part C: Up to D13 Part D: UP to D12
Reported as:
Mean · h*ng/mL
AUC0-t
h*ng/mLPart A:IPG1094 100 mg SADPartA:IPG1094 300 mg SADPart A:IPG1094 600 mg SADPart A:IPG1094 900mg SADPartA:IPG1094 1200mg SADPart B:IPG1094 600 mg MAD QDPart C:IPG1094 200 mg MAD BIDPartC:IPG1094 300 mg MAD BIDPart D: IPG1094 300 mg FastedPartD: IPG1094 300mg Fed
the SAD group and the single-dose administration (D1) of the MAD group and fasted &Fed status5950 ± 152026100 ± 1410085600 ± 40200157000 ± 93400345000 ± 15100055200 ± 369008500 ± 563028900 ± 1670029700 ± 3710048800 ± 30900
the MAD group after multiple administrations (D10)—————195000 ± 23900063000 ± 25500———
SecondaryCL/F

Apparent clearance following extravascular administration, calculated as Dose/AUC0-inf Part A: 0h before administration(within 1h prior toadministration),0.5,1,1.5,2,2.5,3,4,6,9,12,24,36,48,72,and 96 h after administration. Part B: 0h before AMadministration(within 1h before AM administration),0.5,1,1.5,2,2.5,3,4,6,9,12,24h after administration on Day 1 and Day 10;at 0h beforeadministration(within 1h prior to administration)on day 4,day 6 and Day 8;at 36,48,72,and 96h after thelast administration on Day 10. Part C: 0h before AMadministration(within 1h before AM administration),0.5,1,1.5,2,2.5,3,4,6,9,12(within 1h before PMadministration),24h(within 1h beforeAMadministration of Day 2)after administration on Day 1 and Day 10;at 0h before administration(within1h priorto AM administration)on day 3,day4,day 5 day 6 and Day 8;at 48,72h after the AM administrationon Day 10. Part D:pre-dose(within 1h before administration),0.5,1,1.5,2,2.5,3,4,5,6,9,12,24,36,48,72h after administration

Time frame:
Part A: UP to D5 Part B: UP to D14 Part C: Up to D13 Part D: UP to D12
Reported as:
Mean · L/h
CL/F
L/hPart A:IPG1094 100 mg SADPart A: IPG1094 300 mg SADPart A: IPG1094 600 mg SADPart A: IPG1094 900mg SADPart A: IPG1094 1200mg SADPart B: IPG1094 600 mg MAD QDPart C: IPG1094 200 mg MAD BIDPart C: IPG1094 300 mg MAD BIDPart D: IPG1094 300 mg FastedPartD: IPG1094 300mg Fed
the SAD group and the single-dose administration (D1) of the MAD group and fasted &Fed status14.8 ± 3.7313.7 ± 7.629.07 ± 5.948.45 ± 6.184.21 ± 2.15—————
the MAD group after multiple administrations (D10)—————7.44 ± 5.593.68 ± 1.64———

Adverse events

Collected over Part A (SAD):From signed ICF up to D8;Part B (MAD):From signed ICF up to D17;Part C (MAD):From signed ICF up to D17;Part D (FE):From signed ICF up to D12;. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
IPG1094 100 mg SAD0/4 (0%)0/4 (0%)0/4 (0%)
IPG1094 300 mg SAD0/6 (0%)0/6 (0%)2/6 (33.3%)
IPG1094 600 mg SAD0/6 (0%)0/6 (0%)3/6 (50%)
IPG1094 900mg SAD0/6 (0%)0/6 (0%)3/6 (50%)
IPG1094 1200mg SAD0/6 (0%)0/6 (0%)6/6 (100%)
IPG1094 600 mg MAD QD0/6 (0%)0/6 (0%)6/6 (100%)
IPG1094 200 mg MAD BID0/6 (0%)0/6 (0%)6/6 (100%)
IPG1094 300 mg MAD BID0/6 (0%)0/6 (0%)6/6 (100%)
Part D:Fasted0/12 (0%)0/12 (0%)5/12 (41.7%)
Part D: Fed0/12 (0%)0/12 (0%)7/12 (58.3%)
PartA: Placebo0/10 (0%)0/10 (0%)5/10 (50%)
PartB: Placebo0/2 (0%)0/2 (0%)2/2 (100%)
Part C: Placebo0/4 (0%)0/4 (0%)2/4 (50%)
Most frequent other events
Most frequent other events
EventIPG1094 100 mg SADIPG1094 300 mg SADIPG1094 600 mg SADIPG1094 900mg SADIPG1094 1200mg SADIPG1094 600 mg MAD QDIPG1094 200 mg MAD BIDIPG1094 300 mg MAD BIDPart D:FastedPart D: FedPartA: PlaceboPartB: PlaceboPart C: Placebo
Nervous system disordersNervous system disorders0/41/62/62/66/66/65/66/64/125/121/102/22/4
Gastrointestinal disordersGastrointestinal disorders0/40/62/60/64/63/62/65/60/120/120/101/21/4
Musculoskeletal and connective tissue disordersMusculoskeletal and connective tissue disorders0/40/60/60/61/61/62/62/60/121/120/100/20/4
Skin and subcutaneous tissue disordersSkin and subcutaneous tissue disorders0/41/60/60/60/60/61/60/60/120/123/100/20/4
General disorders and administration site conditionsGeneral disorders0/40/60/60/60/60/60/61/61/121/121/100/21/4
Infections and infestationsInfections and infestations0/40/60/61/60/60/60/60/60/121/121/100/20/4
Respiratory, thoracic and mediastinal disordersRespiratory, thoracic and mediastinal disorders0/40/60/61/60/60/61/61/60/120/120/100/20/4
InvestigationsInvestigations0/40/60/60/60/61/60/61/61/121/120/100/20/4

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)IPG1094 300 mg SADIPG1094 100 mg SADIPG1094 600 mg SADIPG1094 900mg SADIPG1094 1200mg SADIPG1094 600 mg MAD QDIPG1094 200 mg MAD BIDIPG1094 300 mg MAD BIDPartA: PlaceboPartB: PlaceboPart C: PlaceboPart D IPG1094 300 mg Fasted-FedPart D IPG1094 300 mg Fed-FastedTotal
<=18 years00000000000000
Between 18 and 65 years6466667610247676
>=65 years00000000000000
Age, Continuous
Age, Continuous(years)IPG1094 300 mg SADIPG1094 100 mg SADIPG1094 600 mg SADIPG1094 900mg SADIPG1094 1200mg SADIPG1094 600 mg MAD QDIPG1094 200 mg MAD BIDIPG1094 300 mg MAD BIDPartA: PlaceboPartB: PlaceboPart C: PlaceboPart D IPG1094 300 mg Fasted-FedPart D IPG1094 300 mg Fed-FastedTotal
Mean30.0 ± 9.5927.3 ± 5.2529.3 ± 6.2828.7 ± 5.0126.3 ± 3.1432.3 ± 4.5529.4 ± 5.4431.0 ± 9.5327.8 ± 5.2733.5 ± 6.3627.5 ± 4.6530.1 ± 5.1830.2 ± 1.7229.6 ± 5.79
Sex: Female, Male
Sex: Female, Male(Participants)IPG1094 300 mg SADIPG1094 100 mg SADIPG1094 600 mg SADIPG1094 900mg SADIPG1094 1200mg SADIPG1094 600 mg MAD QDIPG1094 200 mg MAD BIDIPG1094 300 mg MAD BIDPartA: PlaceboPartB: PlaceboPart C: PlaceboPart D IPG1094 300 mg Fasted-FedPart D IPG1094 300 mg Fed-FastedTotal
Female334424324102335
Male312242446145341
Race (NIH/OMB)
Race (NIH/OMB)(Participants)IPG1094 300 mg SADIPG1094 100 mg SADIPG1094 600 mg SADIPG1094 900mg SADIPG1094 1200mg SADIPG1094 600 mg MAD QDIPG1094 200 mg MAD BIDIPG1094 300 mg MAD BIDPartA: PlaceboPartB: PlaceboPart C: PlaceboPart D IPG1094 300 mg Fasted-FedPart D IPG1094 300 mg Fed-FastedTotal
American Indian or Alaska Native01000000000012
Asian312232130011019
Native Hawaiian or Other Pacific Islander00000000000000
Black or African American00000010000001
White3224335310236551
More than one race00000000000000
Unknown or Not Reported00200100000003
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)IPG1094 300 mg SADIPG1094 100 mg SADIPG1094 600 mg SADIPG1094 900mg SADIPG1094 1200mg SADIPG1094 600 mg MAD QDIPG1094 200 mg MAD BIDIPG1094 300 mg MAD BIDPartA: PlaceboPartB: PlaceboPart C: PlaceboPart D IPG1094 300 mg Fasted-FedPart D IPG1094 300 mg Fed-FastedTotal
Hispanic or Latino011002212212115
Not Hispanic or Latino635664558035561
Unknown or Not Reported00000000000000
BMI
BMI(kg/m²)IPG1094 300 mg SADIPG1094 100 mg SADIPG1094 600 mg SADIPG1094 900mg SADIPG1094 1200mg SADIPG1094 600 mg MAD QDIPG1094 200 mg MAD BIDIPG1094 300 mg MAD BIDPartA: PlaceboPartB: PlaceboPart C: PlaceboPart D IPG1094 300 mg Fasted-FedPart D IPG1094 300 mg Fed-FastedTotal
Mean24.2 ± 3.10524.45 ± 3.51523.07 ± 1.96927.88 ± 2.16923.02 ± 3.04325.88 ± 3.27426.26 ± 2.98524.88 ± 2.84125.09 ± 3.44623.1 ± 0.56625.23 ± 2.31124.67 ± 2.96923.32 ± 1.42624.63 ± 3.198
08

Study locations

1 site
  • Scientia Clinical Research Ltd
    Randwick, New South Wales 2031, Australia
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Sep 2021 to primary completion in Jul 2022, 9 months.

Results were first posted in May 2026, 3 years 9 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 16, 2021
First posted
Nov 8, 2021
StartActual
Sep 27, 2021
Primary completionActual
Jul 25, 2022
CompletionActual
Jul 25, 2022
Results first posted
May 1, 2026
Last update
May 1, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 1, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05112159
Lead sponsor
Nanjing Immunophage Biotech Co., Ltd
Responsible party
Sponsor
First posted
Nov 8, 2021
Start date
Sep 27, 2021
Primary completion
Jul 25, 2022
Completion
Jul 25, 2022
Results posted
May 1, 2026
Last update
May 1, 2026

Study contacts

Christopher Argent
principal investigator · Scientia Clinical Research Ltd

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: MIF Inhibitor IPG1094

Start the discussion